Taken together, these data demonstrate that circ-EGFR enhances cetuximab sensitivity in CRC cells, suggesting that circ-EGFR may be a potential predictor of cetuximab response in metastatic colorectal cancer (mCRC). This evidence concerns the gene EGFR and metastatic colorectal cancer.